Company: OCEA
Filing Date: 2025-01-13
Form Type: 10-Q
Source: 0001493152-25-001880
Chunk: 172

Company: Ocean Biomedical, Inc.
Filing Date: 2025-01-13
Form: 10-Q
Item: Item 8
Chunk 172
---
 are not limited
to, the information below and the information discussed in the section titled “Cautionary Note Regarding Forward-looking Statements.”

On
February 14, 2023, we consummated a business combination (the “Business Combination”) pursuant to that certain Agreement
and Plan of Merger, dated August 31, 2022, as amended on December 5, 2022 by Amendment No. 1 (as amended, the “Business Combination
Agreement”), by and among Ocean Biomedical, Inc., formerly known as Aesther Healthcare Acquisition Corp. (the “Company”),
AHAC Merger Sub, Inc., a Delaware corporation, Aesther Healthcare Sponsor, LLC (the “Sponsor”), in its capacity as purchaser
representative, Ocean Biomedical Holdings, Inc., formerly known as Ocean Biomedical, Inc., a Delaware corporation (“Legacy Ocean”),
and Dr. Chirinjeev Kathuria, in his capacity as seller representative. In connection with the closing of the Business Combination (the
“Closing”), the Company changed its name from “Aesther Healthcare Acquisition Corp.” to “Ocean Biomedical,
Inc.” References to the “Company”, “Ocean Biomedical”, “we”, “us” and “our”
refer to the Legacy Ocean prior to the Closing of the Business Combination and Ocean Biomedical, Inc., formerly known as Aesther Healthcare
Corp., on a consolidated basis with Legacy Ocean, for periods after the Closing of the Business Combination.

Overview

We
are a biopharmaceutical company that seeks to bridge the “bench-to-bedside” gap between medical research discoveries and
patient solutions. We do this by leveraging our strong relationships with research universities and medical centers to license their
inventions and technologies with the goal of developing them into products that address diseases with significant unmet medical needs.
We believe that our differentiated business model positions us to capture inventions created at these institutions that might otherwise
fail to be commercialized to benefit patients. Our team of accomplished scientists, business professionals and entrepreneurs bring together
the interdisciplinary expertise and resources required to develop and commercialize a diverse portfolio of assets. We are organized around
a licensing and subsidiary structure that we believe will enable us to create mutual value both for us and potential licensing partners.
We believe this structure, combined with the professional networks of our leadership team members, allows us to opportunistically build
a continuous pipeline of promising product innovations through our existing and potential future relationships with research institutions.

Our
goal is to